Norepinephrine Transporter–Targeted Cancer Theranostics—New Horizons
Open Access
- 19 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (1) , 44-51
Abstract
In the evolving landscape of precision oncology, this review delineates the role of radiopharmaceuticals targeting the norepinephrine transporter (NET), with a particular focus on the current clinical application of 123I-MIBG diagnostic imaging and 131I-MIBG therapeutics, in particular for pheochromocytoma, neuroblastoma, or paraganglioma. We will also highlight recently introduced 18F-labeled NET targeting imaging radiotracers, which would offer unparalleled resolution, enhanced tumor localization, and staging properties. Complementing these novel second-generation PET agents in a theranostic approach, astatine-211 meta-astatobenzylguanidine (211At-MABG) would leverage the advantages of alpha-particles to selectively target and eradicate NET-expressing tumor cells with minimal off-target effects.Keywords
This publication has 68 references indexed in Scilit:
- The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Phase II study of 131I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOPPediatric Blood & Cancer, 2023
- Malignant prediction in paragangliomas: analysis for clinical risk factorsLangenbeck's Archives of Surgery, 2021
- New PET technologies – embracing progress and pushing the limitsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvementsJournal of Neural Transmission, 2020
- Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma modelEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Nothing but NET: A review of norepinephrine transporter expression and efficacy of131I‐mIBG therapyPediatric Blood & Cancer, 2014
- The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Meta‐[211AT]astatobenzylguanidine: Further evaluation of a potential therapeutic agentInternational Journal of Cancer, 1994
- Norepinephrine analog detects pheochromocytoma1982